National Cancer Institute; Notice of Closed Meeting, 9933 [2013-03117]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 29 / Tuesday, February 12, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; Ancillary
Studies To Large Clinical Projects Grant
Review.
Date: March 1, 2013.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,, Suite
818, 6706 Democracy Blvd., Bethesda, MD
20892, (Virtual Meeting).
Contact Person: Charles N. Rafferty, Ph.D.,
Chief, Scientific Review Branch, 6701
Democracy Boulevard, Suite 800, National
Institute of Arthritis, Musculoskeletal and
Skin Diseases, National Institutes of Health,
Bethesda, MD 20817, 301–594–5019,
charles.rafferty@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: February 5, 2013.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
development resources for potential
new cancer diagnostics. The outcome of
the evaluation will be information for
consideration by an internal NCI
committee that will decide whether
NCI/DCTD should support the requests
and make available contract resources
for development of the potential
diagnostics to improve the treatment of
cancer. The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Clinical
Assay Development Program (CADP).
Date: April 5, 2013.
Time: 9:00 a.m.–4:00 p.m.
Agenda: To evaluate requests for
development resources for potential new
diagnostics for cancer.
Place: 5635 Fishers Lane, Room 508,
Rockville, MD 20852.
Contact Person: Tracy G. Lively, Ph.D.,
Executive Secretary, Cancer Diagnosis
Program (CADP), National Cancer Institute,
NIH, 6130 Executive Boulevard, Room
6035A, Bethesda, MD 20892, 301–496–8639,
livelyt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
[FR Doc. 2013–03113 Filed 2–11–13; 8:45 am]
Dated: February 6, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2013–03117 Filed 2–11–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
tkelley on DSK3SPTVN1PROD with NOTICES
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
VerDate Mar<15>2010
16:40 Feb 11, 2013
Jkt 229001
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
9933
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Monitoring of National Suicide
Prevention Lifeline (OMB No. 0930–
0274)—Revision
This proposed project renewal
includes the continuation of previously
approved data collection activities
Monitoring of National Suicide
Prevention Lifeline Form (OMB No.
0930–0274) in an effort to advance the
understanding of crisis hotline
utilization and its impact. Out of the
previously approved 11 data collection
instruments and consents, only 6 will be
utilized through this revision. The
Substance Abuse and Mental Health
Services Administration’s (SAMHSA),
Center for Mental Health Services
(CMHS) funds a National Suicide
Prevention Lifeline Network, consisting
of a toll-free telephone number that
routes calls from anywhere in the
United States to a network of local crisis
centers. In turn, the local centers link
callers to local emergency, mental
health, and social service resources.
The overarching purpose of the
proposed Monitoring of National
Suicide Prevention Lifeline—Revision is
to examine the impact of motivational
training and safety planning (MI/SP)
with callers who have expressed
suicidal desire (i.e., follow-up
interviews with callers and counselors).
In total this effort includes three data
collection instruments and three
associated data collection consents.
Clearance is being requested to
continue the previously approved data
collection activities to continue caller
and counselor follow-up assessment
activities which will examine the
process and impact of motivational
training and safety planning (MI/SP)
with callers who have expressed
suicidal ideation. The data collected
through the renewal of these data
collection activities will ultimately help
SAMHSA to understand and direct their
crisis hotline lifesaving initiatives. The
data collection activities are enumerated
below.
Funded crisis centers will train
counselors to implement an
intervention with callers during the
initial call to a center, which
incorporates aspects of motivational
interviewing and safety planning (MI/
SP) and utilizes an evidence-based
practice model to provide follow-up to
callers who have expressed a suicidal
desire. An assessment of MI/SP fidelity
and process measures will be
incorporated into the design through the
E:\FR\FM\12FEN1.SGM
12FEN1
]]>Agencies
[Federal Register Volume 78, Number 29 (Tuesday, February 12, 2013)]
[Notices]
[Page 9933]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03117]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for development resources for potential new cancer diagnostics. The
outcome of the evaluation will be information for consideration by an
internal NCI committee that will decide whether NCI/DCTD should support
the requests and make available contract resources for development of
the potential diagnostics to improve the treatment of cancer. The
research proposals and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the
proposed research projects, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Clinical Assay Development Program (CADP).
Date: April 5, 2013.
Time: 9:00 a.m.-4:00 p.m.
Agenda: To evaluate requests for development resources for
potential new diagnostics for cancer.
Place: 5635 Fishers Lane, Room 508, Rockville, MD 20852.
Contact Person: Tracy G. Lively, Ph.D., Executive Secretary,
Cancer Diagnosis Program (CADP), National Cancer Institute, NIH,
6130 Executive Boulevard, Room 6035A, Bethesda, MD 20892, 301-496-
8639, livelyt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 6, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-03117 Filed 2-11-13; 8:45 am]
BILLING CODE 4140-01-P
